| 9:30 AM - 10:25 AM | Chair’s opening remark's followed by: Bag to bedside: IV fluid essentials
- Types of IV fluids and indications
- Administering medications
- Monitoring and adjusting therapy
- Special populations and considerations
- Pharmacist as a key contributor
|
| 10:40 AM - 11:25 AM | Fluid Stewardship at East Lancashire Hospitals – what we did and why
- Why implement a Fluid Stewardship programme?
- Pre implementation survey
- Setting up Multi-disciplinary Team
Sponsored by Baxter Healthcare UK Ltd |
| 11:40 AM - 12:25 PM | Licensed ready-to-use and ready-to-administer IV products – Can we put a price on safety?
- Understand the differences between RTU and RTA IV products
- Evaluate the effect of RTU and RTA products on medication safety and the efficiency of administration
- Explore cost-benefit considerations related to RTU and RTA IV medicines
- Identify challenges in the implementation of RTU and RTA products in clinical practice
- Discuss real-world example(s) of improved patient safety through RTU and RTA adoption
|
| 12:40 PM - 1:25 PM | Transitioning to NRFit™ – Where are we now, and what can we do to manage patient safety risks?
- Describe the purpose and design of NRFit™
- Assess the current progress of NRFit™ adoption in clinical settings
- Identify possible safety risks related to neuraxial and regional anaesthesia connectors
- Discuss effective strategies for a smooth transition to NRFit™ in healthcare facilities
- Explore methods for training pharmacists on NRFit™ implementation
|
| 1:40 PM - 2:25 PM | Shared responsibility: Enhancing occupational safety through pharmacist–nurse collaboration
- Managing hazardous drugs (HD) in clinical practice: Insights from Germany and Switzerland
- Occupational exposure to carcinogens, mutagens, reprotoxins (CMRs): understanding the risks and mitigation strategies
- Closed system transfer devices (CSTDs): enhancing safety through engineering controls
- Pharmacist-nurse synergy: advancing best practices in HD management
Sponsored by: |
| 2:40 PM - 3:25 PM | Complications of IV therapy – CLABSI, thrombophlebitis and extravasation updates
- Define CLABSI, thrombophlebitis and extravasation
- Identify risk factors contributing to IV therapy complications
- Review the latest guidelines and recommendations for preventing and managing these complications
- Discuss the role of pharmacists in early recognition and intervention
- Practical evidence/case study that highlights recent advancements in IV therapy safety
|
| 3:40 PM - 4:25 PM | Initiatives in IV safety – what are we doing in the NHS to drive innovation and improvement?
- Examine key NHS initiatives aimed at improving IV medication safety
- Assess the impact of technological innovations in IV therapy administration
- Discuss strategies for reducing medication errors and enhancing patient safety
- Explore the role of policy changes and national standards in shaping IV safety practices
- Identify opportunities for collaboration and further improvements in IV safety
|
